Compare AbbVie Inc (ABBV) vs Shopify Inc. (SHOP) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Shopify (SHOP) trades at $121.88, up 2.03% on the day, with a bullish technical setup showing strong moving average signals and support near $117. Revenue grew to $11.56B in 2025 with a 10.77% net margin, though valuation multiples remain elevated. Recent news highlights Bank of America reinstating a Buy rating with a $150 target, citing AI commerce tools and partnership developments.

Outlook is positive with analyst consensus at $149.10 and 63% Buy ratings, but high P/E of 117.78 poses valuation risk. Key opportunities include AI-driven growth and expanding merchant services, while risks involve competitive pressures and reliance on e-commerce trends. Cash flow trends show improving operations, supporting continued investment in innovation.